Aclarion Expands CLUE Trial to New Jersey for Chronic Low Back Pain Diagnosis

Aclarion, Inc., a healthcare technology company specializing in chronic low back pain diagnosis, has announced the expansion of its Clinical Utility and Economic (CLUE) trial to New Jersey. This multi-center study aims to assess how frequently Nociscan's artificial intelligence-generated data influences initial treatment plans for patients suffering from chronic low back pain.

Dr. Justin Kubeck, an orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms River, NJ, has joined the growing network of spine surgeons participating in the CLUE trial. Dr. Kubeck is the second surgeon to join since the trial's announcement earlier this month, following Dr. John Keller, a neurosurgical spine surgeon in Michigan.

The CLUE trial is designed to build a comprehensive body of data supporting the real-world value of integrating Nociscan's AI-generated data into existing diagnostic evaluation methods for chronic low back pain treatment. Aclarion expects more spine surgeons to join the trial in the coming months, which will rapidly provide compelling data to payers regarding Nociscan's impact on the decision-making process during critical treatment planning stages.

Dr. Kubeck emphasized the importance of individualized treatment plans for patients, stating, "There is a protocol that I follow; I don't ever just go in and do surgery. For me, developing the best treatment plan for an individual patient is very proceduralized." He added that Nociscan would serve as an invaluable decision support tool when evaluating diagnosis and treatment options.

Chronic low back pain affects approximately 266 million people globally, underscoring the significance of improved diagnostic tools. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology objectively quantifies chemical biomarkers associated with disc pain, using proprietary algorithms to highlight potential pain sources.

Ryan Bond, Chief Strategy Officer at Aclarion, highlighted the importance of real-world evidence in evaluating emerging diagnostic tools. He stated, "Real world evidence is incredibly valuable when evaluating the influence and utility of an emerging diagnostic tool and when this evidence can be rapidly secured by experienced surgeons through a trial like CLUE, it becomes a critical tool for driving early payer coverage decisions."

The expansion of the CLUE trial represents a significant step forward in Aclarion's mission to optimize clinical treatments for chronic low back pain. By leveraging Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms, Nociscan aims to provide critical insights into the location of a patient's low back pain, enabling physicians to develop more targeted and effective treatment strategies.

As the trial progresses, the healthcare industry will be watching closely to see how Nociscan's AI-driven approach may potentially transform the diagnosis and treatment of chronic low back pain, potentially offering hope to millions of sufferers worldwide.

For more information about Aclarion and its Nociscan technology, interested parties can visit www.aclarion.com.